Primary Care Patient Interest in Multi-Cancer Early Detection for Cancer Screening

• Published in: Journal of personalized medicine Vol. 13; no. 11; p. 1613
• Main Authors: Myers, Ronald E, Hallman, Mie H, Shimada, Ayako, DiCarlo, Melissa, Davis, Kaitlyn, Leach, William T, Jackson, Hattie, Indictor, Amanda, Chambers, Christopher V
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.11.2023
• Subjects: Blood; Blood tests; Cancer; Cancer patients; Cancer screening; Clinical trials; Consent; Decision making; Diagnosis; Electronic health records; Mammography; Medical examination; Medical imaging; Medical practices; Medical records; Medical screening; Older people; Oncology, Experimental; Patients; Perceptions; Polls & surveys; Precision medicine; Primary care; Sociodemographics; Surveys; Urban health; multi-cancer early detection tests; primary care; cancer screening
• ISSN: 2075-4426; 2075-4426
• DOI: 10.3390/jpm13111613

Multi-cancer early detection (MCED) tests are being developed, but little is known about patient receptivity to their use for cancer screening. The current study assessed patient interest in such testing. Our team conducted a prospective, observational study among primary care patients in a large, urban health system. They were asked to complete a telephone survey that briefly described a new blood test in development to identify multiple types of cancer, but was not currently recommended or covered by insurance. The survey included items to assess respondent background characteristics, perceptions about MCED testing, and interest in having such an MCED test. We also used multivariable analyses to identify factors associated with patient interest in test use. In 2023, we surveyed 159 (32%) of 500 identified patients. Among respondents, 125 (79%) reported a high level of interest in having an MCED test. Interest was not associated with personal background characteristics, but was positively associated with the following expectations: testing would be recommended for cancer screening, be convenient, and be effective in finding early-stage disease (OR = 11.70, 95% CI: 4.02, 34.04, < 0.001). Research is needed to assess patient interest and actual uptake when detailed information on testing is presented in routine care.